Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (390)	6/6/2002 3:22:02 AM
From: nigel bates	Respond to of 1022

ROCHE AND GENMAB ANNOUNCE MAJOR EXPANSION OF ANTIBODY COLLABORATION. ROCHE TO INVEST $20 MILLION IN GENMAB Basel, Switzerland and Copenhagen, Denmark; June 6, 2002 Roche and Genmab A/S (CSE: GEN and Neuer Markt: GE9D) announced today a broad expansion of their current collaboration with Genmab for the creation and development of human antibody therapeutic products for life-threatening and debilitating diseases. Roche is also making an equity investment totaling $20 Million (approximately DKK 170 Million) at a price of DKK 180 per share. This expanded program involves a number of new disease targets from Roche. Genmab expects to initiate approximately fifteen new projects in the coming year across a number of therapeutic areas. The program is coordinated by Roche's proteomics group and will focus on the company's commitment to the development of biologicals as innovative new products...